Blood News and Research

RSS

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

A Nevada jury has awarded three plaintiffs $500 million in punitive damages after finding negligence.

11 Apr 2013

Orthopaedic surgeons should recommend weight loss to patients prior to joint replacement

The obesity epidemic in America and its impact on musculoskeletal health, as well as related treatment outcomes and costs, was discussed during the AAOS Now forum, "Obesity, Orthopaedics and Outcomes," at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons at McCormick Place in Chicago.

11 Apr 2013

Roundup: Minn. Democrats push pay hike for nursing home workers; Colo. official warns of possible exchange delays due to IT

A selection of health policy stories from Minnesota, Colorado, New York, Delaware, Georgia, Oregon, Connecticut, Pennsylvania, Arizona, Massachusetts and California.

11 Apr 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013

Coenzyme Q10 offsets cellular changes that are linked to side-effect of some statin drugs: Study

A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.

11 Apr 2013

Examining global partnerships on World Health Day

Noting Sunday "was World Health Day, and marked the 65th anniversary of the founding of the World Health Organization," Andrea Durkin, senior director of global government affairs and policy for Abbott, writes in the U.S. Global Leadership Coalition blog.

10 Apr 2013

Study reveals high blood pressure and obesity are no longer confined to wealthy countries

High blood pressure and obesity are no longer confined to wealthy countries, a new study has found. These health risks have traditionally been associated with affluence, and in 1980, they were more prevalent in countries with a higher income.

10 Apr 2013

Study shows human blood contains 1000’s of autoantibodies to clear cellular debris caused by injury, disease

In a study that suggests a new frontier in immunology, scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) report on evidence that shows human blood contains thousands of autoantibodies that bind specifically to antigens from organs and tissues all over the body and act to clear cellular debris that results from injury and disease.

10 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

Study: Non-traditional well-being risks can impact workers' productivity

In addition to health-related risk factors, some non-traditional "well-being risks" can have a significant impact on workers' productivity, reports a study in the April Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

10 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

OTraces completes Phase II testing for blood test that detects breast cancer

OTraces, Inc., a Maryland-based biotech company developing blood tests for cancer diagnosis, announces completion of Phase II testing for a blood test that screens women for breast cancer.

10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Scientists from UCLA's Fielding School of Public Health led by Julia Heck, an assistant researcher in the school's epidemiology department and a member of UCLA's Jonsson Comprehensive Cancer Center, have found a possible link between exposure to traffic-related air pollution and several childhood cancers.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Blood News and Research

FDA accepts Merck's NDA for NOXAFIL tablets

Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

Orthopaedic surgeons should recommend weight loss to patients prior to joint replacement

Roundup: Minn. Democrats push pay hike for nursing home workers; Colo. official warns of possible exchange delays due to IT

Scientists demonstrate feasibility of using already-approved drugs against pathogens

Coenzyme Q10 offsets cellular changes that are linked to side-effect of some statin drugs: Study

Examining global partnerships on World Health Day

Study reveals high blood pressure and obesity are no longer confined to wealthy countries

Study shows human blood contains 1000’s of autoantibodies to clear cellular debris caused by injury, disease

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

Study: Non-traditional well-being risks can impact workers' productivity

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

OTraces completes Phase II testing for blood test that detects breast cancer

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

New immunotherapies are seldom developed for childhood cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News